The majority of patients with advanced breast cancer were previously treated with chemotherapy. Hematologic Reversible granulocytopenia is the major dose-limiting toxicity reported with Navelbine. It is not cumulative over time. Granulocyte nadirs occur 7 to 10 days after the dose and usually recover within the following 7 to 14 days. Prophylactic hematologic growth factors have not been routinely used with Navelbine.
Few patients require transfusion.
Thrombocytopenia is rare. Mild to moderate thrombocytosis is observed but it is not associated with coagulopathies. Neurologic Mild to moderate peripheral neuropathy manifested by paresthesia and hypesthesia are the most frequently reported neurologic toxicities. Neurotoxicity may be reversible upon discontinuation of Navelbine. Tumor pain and jaw pain have been reported with Navelbine, as with other vinca alkaloids.